Key facts
- Ormoni Biosciences’s last known valuation is $15.1M (Feb 2025).
- It has raised $5.6M; the latest was Seed Round ($5.6M) in Feb 2025.
- Notable investors include True Ventures, Pillar VC.
- Status: Privately Held (backing).
Investors
2- ·The complete investor list — 2 names
- ·Watchlist + deal alerts for Ormoni Biosciences
- ·The full record, as it builds
Funding rounds
No funding rounds for Ormoni Biosciences are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Ormoni Biosciences
Developer of an intelligent drug design platform focused on creating novel therapies. The company generates large-scale polypeptide drug data, trains its proprietary drug model for optimal therapy development, and accelerates the process of designing and producing drugs, providing healthcare providers with faster access to innovative treatments for patients in need.
- Sector
- Healthcare
- HQ
- Boston, MA, United States
- Website
- ormoni.bio/
- Ownership
- Privately Held (backing)
Ormoni Biosciences doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Ormoni Biosciences shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Ormoni Biosciences in its N-PORT filings yet. We sweep new filings monthly.